Holdings (Monthly)
Guide ↗
Invesco Biotechnology & Genome ETF
· Invesco Exchange-Traded Fund Trust| # | Name | Ticker | Since | Shares | Value | % Port | Cat |
|---|---|---|---|---|---|---|---|
| 1 | Invesco Private Prime Fund | N/A | Jan 2026 | 26,781,082 | $26.8M | 10.18% | STIV |
| 2 | Illumina, Inc. | 452327109 | Jan 2026 | 103,203 | $14.9M | 5.68% | EC |
| 3 | Gilead Sciences, Inc. | 375558103 | Jan 2026 | 103,770 | $14.7M | 5.60% | EC |
| 4 | Amgen Inc. | 031162100 | Jan 2026 | 38,885 | $13.3M | 5.06% | EC |
| 5 | Biogen Inc. | 09062X103 | Jan 2026 | 73,517 | $13.2M | 5.03% | EC |
| 6 | United Therapeutics Corp. | 91307C102 | Jan 2026 | 27,241 | $12.8M | 4.86% | EC |
| 7 | Regeneron Pharmaceuticals, Inc. | 75886F107 | Jan 2026 | 17,072 | $12.7M | 4.81% | EC |
| 8 | Incyte Corp. | 45337C102 | Jan 2026 | 122,358 | $12.2M | 4.66% | EC |
| 9 | Invesco Private Government Fund | N/A | Jan 2026 | 10,305,622 | $10.3M | 3.92% | STIV |
| 10 | Amicus Therapeutics, Inc. | 03152W109 | Jan 2026 | 716,939 | $10.2M | 3.90% | EC |
| 11 | Alnylam Pharmaceuticals, Inc. | 02043Q107 | Jan 2026 | 29,936 | $10.1M | 3.85% | EC |
| 12 | Dynavax Technologies Corp. | 268158201 | Jan 2026 | 619,803 | $9.6M | 3.65% | EC |
| 13 | Qiagen N.V. | N72482156 | Jan 2026 | 150,201 | $8.1M | 3.07% | EC |
| 14 | MannKind Corp. | 56400P706 | Jan 2026 | 1,382,171 | $8.0M | 3.04% | EC |
| 15 | Ionis Pharmaceuticals, Inc. | 462222100 | Jan 2026 | 90,302 | $7.5M | 2.84% | EC |
| 16 | Acadia Pharmaceuticals Inc. | 004225108 | Jan 2026 | 296,675 | $7.5M | 2.84% | EC |
| 17 | Royalty Pharma PLC | G7709Q104 | Jan 2026 | 178,379 | $7.4M | 2.83% | EC |
| 18 | Catalyst Pharmaceuticals, Inc. | 14888U101 | Jan 2026 | 301,597 | $7.3M | 2.79% | EC |
| 19 | BioMarin Pharmaceutical Inc. | 09061G101 | Jan 2026 | 127,758 | $7.2M | 2.75% | EC |
| 20 | Bio-Techne Corp. | 09073M104 | Jan 2026 | 111,680 | $7.2M | 2.72% | EC |
| 21 | Collegium Pharmaceutical, Inc. | 19459J104 | Jan 2026 | 155,580 | $7.1M | 2.72% | EC |
| 22 | Exelixis, Inc. | 30161Q104 | Jan 2026 | 167,824 | $6.9M | 2.64% | EC |
| 23 | Halozyme Therapeutics, Inc. | 40637H109 | Jan 2026 | 95,817 | $6.9M | 2.61% | EC |
| 24 | BioCryst Pharmaceuticals, Inc. | 09058V103 | Jan 2026 | 1,038,146 | $6.8M | 2.60% | EC |
| 25 | Neurocrine Biosciences, Inc. | 64125C109 | Jan 2026 | 50,198 | $6.8M | 2.60% | EC |
| 26 | PTC Therapeutics, Inc. | 69366J200 | Jan 2026 | 88,821 | $6.7M | 2.55% | EC |
| 27 | Protagonist Therapeutics, Inc. | 74366E102 | Jan 2026 | 80,859 | $6.6M | 2.52% | EC |
| 28 | Vericel Corp. | 92346J108 | Jan 2026 | 182,370 | $6.6M | 2.50% | EC |
| 29 | TG Therapeutics, Inc. | 88322Q108 | Jan 2026 | 221,373 | $6.5M | 2.48% | EC |
| 30 | Repligen Corp. | 759916109 | Jan 2026 | 42,392 | $6.3M | 2.41% | EC |
| 31 | Madrigal Pharmaceuticals, Inc. | 558868105 | Jan 2026 | 12,061 | $5.9M | 2.24% | EC |
| 32 | Veracyte, Inc. | 92337F107 | Jan 2026 | 151,832 | $5.8M | 2.20% | EC |
| 33 | Invesco Government & Agency Portfolio | 825252885 | Jan 2026 | 188,757 | $189K | 0.07% | STIV |